CytoSorbents Launches HotSwap™ to Optimize Critical Care Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 19 2026
0mins
Source: Newsfilter
- Launch of HotSwap™: CytoSorbents introduces HotSwap™, designed to expedite the exchange of CytoSorb adsorbers for critically ill patients, enhancing treatment efficiency and reducing nursing workload, thereby improving patient outcomes and survival rates.
- Renewal of Strategic Partnership: The renewal of the exclusive distribution agreement with Aferetica Srl strengthens market position in Italy, with over a decade of collaboration facilitating the widespread adoption of CytoSorb in critical care and cardiac surgery.
- Supportive Clinical Data: At ISICEM 2026, CytoSorbents presented new clinical data showing significant improvements in vasopressor requirements, oxygenation, and fluid balance for ICU patients treated with CytoSorb, with an ICU mortality rate of 32.7%, lower than predicted.
- Enhanced Scientific Leadership: The symposium hosted by CytoSorbents at ISICEM emphasized the importance of personalized treatment, showcasing its leadership in blood purification and further solidifying CytoSorb's role as a frontline therapy across critical illnesses.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CTSO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CTSO
Wall Street analysts forecast CTSO stock price to rise
1 Analyst Rating
0 Buy
1 Hold
0 Sell
Hold
Current: 0.496
Low
0.75
Averages
0.75
High
0.75
Current: 0.496
Low
0.75
Averages
0.75
High
0.75
About CTSO
CytoSorbents Corporation is engaged in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery through blood purification. The Company’s blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its lead product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses that can lead to massive inflammation, organ failure and patient death. Its products also include ECOS-300CY, VetResQ, DrugSorb-ATR, and PuriFi. DrugSorb-ATR is an investigational device that uses equivalent polymer technology to CytoSorb to address a large unmet need for blood thinner reversal in cardiothoracic surgery. ECOS-300CY is used to reduce cytokines and other inflammatory mediators when used in an ex vivo organ perfusion system.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cytosorbents Q1 2026 Earnings Call Insights
- Revenue Growth: Cytosorbents reported a 2% year-over-year revenue increase to $8.9 million in Q1 2026, demonstrating resilience in international markets, particularly with a 13% growth outside Germany despite external challenges.
- Cost Control: Operating expenses decreased to $9.2 million from $10.1 million a year ago, reflecting initial benefits from the strategic headcount and cost reduction program implemented in Q4, with expectations for continued cost reductions.
- Regulatory Delay: The FDA's request for additional mechanistic data may delay the new de novo application for DrugSorb-ATR until late 2026 or early 2027, potentially impacting the company's expansion plans in the U.S. market.
- Market Opportunity: The potential market size for DrugSorb-ATR could reach $500 million to $1 billion if approvals for both Brilinta and DOAC removal are granted, significantly expanding the company's market share, although geopolitical risks from the Middle East pose challenges.
See More
Cytosorbents Q1 Earnings Report Analysis
- Earnings Highlights: Cytosorbents reported a non-GAAP EPS of $0.05 for Q1, indicating a slight year-over-year improvement, yet it falls short of expectations, highlighting ongoing challenges in profitability.
- Revenue Performance: The company generated $8.9 million in revenue for the first quarter, marking a 1.9% year-over-year increase, but it missed market expectations by $460,000, reflecting sluggish sales growth.
- Future Outlook: Cytosorbents aims to achieve cash flow breakeven in the second half of 2026, indicating a strategic pivot to navigate the current market landscape and enhance international sales growth.
- Market Reaction: Despite efforts to expand in international markets, the current financial performance has failed to instill investor confidence, potentially exerting negative pressure on the stock price and reflecting market caution regarding the company's future prospects.
See More
Cytosorbents to Announce Q1 Earnings on May 13
- Earnings Announcement Date: Cytosorbents (CTSO) is set to release its Q1 2023 earnings report on May 13 after market close, with a consensus EPS estimate of -$0.06, indicating ongoing challenges in profitability.
- Revenue Growth Expectations: The anticipated revenue for Q1 is $9.36 million, reflecting a 7.2% year-over-year increase, suggesting that despite profitability pressures, the company is achieving steady revenue growth amid international sales expansion.
- Historical Performance Review: Over the past two years, Cytosorbents has only beaten EPS estimates 13% of the time and revenue estimates 50% of the time, highlighting uncertainty in financial performance that may affect investor confidence.
- Future Outlook: Cytosorbents has outlined a path to cash flow breakeven by the second half of 2026, indicating strategic planning for international market expansion aimed at improving long-term financial health.
See More
CytoSorbents Reports 4% Revenue Growth in 2025
- Annual Revenue Growth: CytoSorbents achieved a full-year revenue of $37.1 million in 2025, reflecting a 4% increase year-over-year, primarily driven by strong performance in international markets, indicating the company's potential for global expansion.
- Gross Margin Performance: The company reported a gross margin of 71% for the full year and 74% in Q4, showcasing improved manufacturing efficiencies that enhance profitability in the competitive medical device sector.
- Challenges in Germany: Sales in Germany declined by 10% to $11.8 million, reflecting the near-term impact of restructuring efforts, although the company is implementing strategies to improve market performance and restore growth.
- Cost Structure Optimization: Operating expenses remained flat at $41.2 million, yet through cost reductions and a strengthened balance sheet, the company aims to achieve cash flow breakeven in the second half of 2026, demonstrating potential for sustainable growth.
See More
Cytosorbents Q4 2025 Earnings Call Insights
- Sales Growth: Cytosorbents reported full-year 2025 sales revenue of $37.1 million, a 4% increase year-over-year, with direct sales outside Germany rising by 13%, indicating successful international market expansion.
- Challenges in Germany: Despite a 10% decline in German sales to $11.8 million, management noted early signs of improvement in Q1 2026, suggesting that restructuring efforts are beginning to yield positive results.
- FDA Progress and Product Launch: Although the FDA denied the initial DrugSorb-ATR submission, management confirmed no safety concerns and plans to focus on remaining issues for a new submission, while launching the PuriFi hemoperfusion pump to expand market access.
- Financial Performance and Outlook: Q4 2025 revenue was $9.2 million with a gross margin increase to 74%; despite an operating loss of $4.6 million, management remains optimistic about achieving cash flow breakeven in the second half of 2026.
See More
Cytosorbents Reports Q4 and Full Year 2025 Financial Results
- Revenue Growth: Cytosorbents reported total revenue of $37.1 million for the fiscal year 2025, marking a 4% increase compared to $35.6 million in 2024, indicating stability and potential growth opportunities in the market despite flat performance on a constant currency basis.
- Gross Margin Improvement: The gross margin for 2025 was 71%, up from 70% in 2024, reflecting positive progress in cost control and pricing strategies, which enhances the company's profitability.
- Net Loss Reduction: The net loss for 2025 decreased to $8.2 million, or $0.13 per share, compared to a net loss of $20.7 million, or $0.38 per share in 2024, demonstrating significant improvement in the company's financial health.
- Adjusted EBITDA Loss Decline: The adjusted EBITDA loss for 2025 was $10.5 million, an improvement from the $11.5 million loss in 2024, showcasing the company's ongoing efforts in operational efficiency and cost management.
See More
Cytosorbents Q1 2026 Earnings Call Insights
- Revenue Growth: Cytosorbents reported a 2% year-over-year revenue increase to $8.9 million in Q1 2026, demonstrating resilience in international markets, particularly with a 13% growth outside Germany despite external challenges.
- Cost Control: Operating expenses decreased to $9.2 million from $10.1 million a year ago, reflecting initial benefits from the strategic headcount and cost reduction program implemented in Q4, with expectations for continued cost reductions.
- Regulatory Delay: The FDA's request for additional mechanistic data may delay the new de novo application for DrugSorb-ATR until late 2026 or early 2027, potentially impacting the company's expansion plans in the U.S. market.
- Market Opportunity: The potential market size for DrugSorb-ATR could reach $500 million to $1 billion if approvals for both Brilinta and DOAC removal are granted, significantly expanding the company's market share, although geopolitical risks from the Middle East pose challenges.
See More
Cytosorbents Q1 Earnings Report Analysis
- Earnings Highlights: Cytosorbents reported a non-GAAP EPS of $0.05 for Q1, indicating a slight year-over-year improvement, yet it falls short of expectations, highlighting ongoing challenges in profitability.
- Revenue Performance: The company generated $8.9 million in revenue for the first quarter, marking a 1.9% year-over-year increase, but it missed market expectations by $460,000, reflecting sluggish sales growth.
- Future Outlook: Cytosorbents aims to achieve cash flow breakeven in the second half of 2026, indicating a strategic pivot to navigate the current market landscape and enhance international sales growth.
- Market Reaction: Despite efforts to expand in international markets, the current financial performance has failed to instill investor confidence, potentially exerting negative pressure on the stock price and reflecting market caution regarding the company's future prospects.
See More
Cytosorbents to Announce Q1 Earnings on May 13
- Earnings Announcement Date: Cytosorbents (CTSO) is set to release its Q1 2023 earnings report on May 13 after market close, with a consensus EPS estimate of -$0.06, indicating ongoing challenges in profitability.
- Revenue Growth Expectations: The anticipated revenue for Q1 is $9.36 million, reflecting a 7.2% year-over-year increase, suggesting that despite profitability pressures, the company is achieving steady revenue growth amid international sales expansion.
- Historical Performance Review: Over the past two years, Cytosorbents has only beaten EPS estimates 13% of the time and revenue estimates 50% of the time, highlighting uncertainty in financial performance that may affect investor confidence.
- Future Outlook: Cytosorbents has outlined a path to cash flow breakeven by the second half of 2026, indicating strategic planning for international market expansion aimed at improving long-term financial health.
See More
CytoSorbents Reports 4% Revenue Growth in 2025
- Annual Revenue Growth: CytoSorbents achieved a full-year revenue of $37.1 million in 2025, reflecting a 4% increase year-over-year, primarily driven by strong performance in international markets, indicating the company's potential for global expansion.
- Gross Margin Performance: The company reported a gross margin of 71% for the full year and 74% in Q4, showcasing improved manufacturing efficiencies that enhance profitability in the competitive medical device sector.
- Challenges in Germany: Sales in Germany declined by 10% to $11.8 million, reflecting the near-term impact of restructuring efforts, although the company is implementing strategies to improve market performance and restore growth.
- Cost Structure Optimization: Operating expenses remained flat at $41.2 million, yet through cost reductions and a strengthened balance sheet, the company aims to achieve cash flow breakeven in the second half of 2026, demonstrating potential for sustainable growth.
See More
Cytosorbents Q4 2025 Earnings Call Insights
- Sales Growth: Cytosorbents reported full-year 2025 sales revenue of $37.1 million, a 4% increase year-over-year, with direct sales outside Germany rising by 13%, indicating successful international market expansion.
- Challenges in Germany: Despite a 10% decline in German sales to $11.8 million, management noted early signs of improvement in Q1 2026, suggesting that restructuring efforts are beginning to yield positive results.
- FDA Progress and Product Launch: Although the FDA denied the initial DrugSorb-ATR submission, management confirmed no safety concerns and plans to focus on remaining issues for a new submission, while launching the PuriFi hemoperfusion pump to expand market access.
- Financial Performance and Outlook: Q4 2025 revenue was $9.2 million with a gross margin increase to 74%; despite an operating loss of $4.6 million, management remains optimistic about achieving cash flow breakeven in the second half of 2026.
See More
Cytosorbents Reports Q4 and Full Year 2025 Financial Results
- Revenue Growth: Cytosorbents reported total revenue of $37.1 million for the fiscal year 2025, marking a 4% increase compared to $35.6 million in 2024, indicating stability and potential growth opportunities in the market despite flat performance on a constant currency basis.
- Gross Margin Improvement: The gross margin for 2025 was 71%, up from 70% in 2024, reflecting positive progress in cost control and pricing strategies, which enhances the company's profitability.
- Net Loss Reduction: The net loss for 2025 decreased to $8.2 million, or $0.13 per share, compared to a net loss of $20.7 million, or $0.38 per share in 2024, demonstrating significant improvement in the company's financial health.
- Adjusted EBITDA Loss Decline: The adjusted EBITDA loss for 2025 was $10.5 million, an improvement from the $11.5 million loss in 2024, showcasing the company's ongoing efforts in operational efficiency and cost management.
See More
